Last update 01 Nov 2024
Genus Oncology LLC
Last update 01 Nov 2024
Overview
Tags
Hemic and Lymphatic Diseases
Neoplasms
Synthetic peptide
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
A Phase I Trial of the MUC1 Inhibitor, GO-203-2c, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GO-203-2c Given Intravenously Daily X21 Repeated Every 28 Days in Patients With Advanced Solid Tumors Including Lymphomas
100 Clinical Results associated with Genus Oncology LLC
Login to view more data
Login to view more data
24 Sep 2021Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Faculty Opinions recommendation of The SIRPα-CD47 immune checkpoint in NK cells.
Author: Kharbanda, Surender
02 Jun 2021Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Faculty Opinions recommendation of Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
Author: Kharbanda, Surender
05 Jun 2020Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Faculty Opinions recommendation of Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Author: Garg, Abhishek ; Kharbanda, Surender
100 Deals associated with Genus Oncology LLC
Login to view more data
100 Translational Medicine associated with Genus Oncology LLC
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 17 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free